Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease.

Geneva, Switzerland — September 30, 2009 — Anavex Life Sciences Corp. (“ANAVEX” or the “Company”) (OTCBB: AVXL) has selected FORENAP Pharma EURL (“FORENAP”) as the contract research organization (CRO) for Phase I clinical trials of ANAVEX 2-73, the company’s lead Alzheimer’s drug candidate.  FORENAP has been involved in pre-clinical and clinical research for 20 years…

Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer’s Disease Clinical Trials

Geneva, Switzerland — September 21, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease.“With sufficient quantities of ANAVEX 2-73 in hand we are an important step closer to the commencement of Phase 1 clinical trials, which…

Anavex Reports Sigma Receptor Review Published in Leading Journal

Geneva, Switzerland — August 27, 2009 — Anavex Life Sciences Corp. (“ANAVEX” or the “Company”) (OTCBB: AVXL) reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology & Therapeutics. The paper provides new insight into sigma-1 receptors and their potential ability…

ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials and Future Growth

Geneva, Switzerland — June 16, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the immediate appointment of Hervé de Kergrohen, MD, MBA, as its Chief Executive Officer (CEO) and director. Dr. de Kergrohen is an accomplished senior executive who has successfully founded and developed numerous life sciences companies throughout his career. With…

Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board

Athens, Greece — February 10, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. Dr. Smith is recognized as one of the world’s most cited researchers in the fields of Alzheimer’s disease, free radical biology and neuroscience and behavior.…

Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study

Athens, Greece — January 30, 2009 — Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease.  ANAVEX 2-73 is scheduled to commence Phase 1 studies in 2009. “The agreement…

Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology

Athens, Greece — December 17, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper published in the current edition…

Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008

Athens, Greece — December 4, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society…